Spots Global Cancer Trial Database for Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC
Official Title: Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in Small Cell Lung Cancer（SCLC）：a Phase II Study
Study ID: NCT03780283
Interventions
Study Description
Brief Summary: Investigations prospectively collected the SCLC patients who received current standard first-line treatment, the response was not progression disease(PD). and then participants receive Anlotinib 12mg, administered as PO on Day1-14 of each 21-day cycle until documented PD or had unacceptable toxicity. This regimen is compared to the effects a observation without treatment after the first-line therapy. The aim of the study is therefore to evaluate the efficacy and safety of Anlotinib as maintenance treatment after first-line chemotherapy in SCLC patients.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The First Hospital of Shijiazhuang, Shijiazhuang, Hebei, China
Contact Details
Name: Yan Zhang, M.D.
Affiliation: The First Hospital of Shijiazhuang
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
